Physician profile
Hadi Atassi
NPI 1407218621
$5,003.68
in general payments reported to CMS, 2019-2025
25 companies · $1,336 in 2025
The $1,336 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $67.00 · 2021: $406 · 2022: $956 · 2023: $421 · 2024: $1,818 · 2025: $1,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,491 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,491.34 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,154.12 | 2021-2025 | Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $841.22 | 2021-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $640.82 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $567.04 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Boston Scientific Corporation | $252.79 | 2021-2024 | Watchman Flx, Captivator II, Wallflex Duodenal |
| Braintree Laboratories, INC. | $250.82 | 2024-2025 | Suflave, Sutab |
| Genzyme Corporation | $227.48 | 2024-2025 | |
| Madrigal Pharmaceuticals | $182.88 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $134.02 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.83 | 2022 | |
| Intercept Pharmaceuticals, INC. | $108.35 | 2022 | |
| Qol Medical, LLC | $98.21 | 2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $80.83 | 2023-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $64.56 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $43.59 | 2025 | Ibsrela |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $40.49 | 2025 | Omvoh |
| Celgene Corporation | $32.80 | 2023-2024 | Zeposia |
| Gilead Sciences, INC. | $29.72 | 2025 | |
| Aimmune Therapeutics, INC. | $23.70 | 2024 | |
| Celltrion USA INC. | $21.06 | 2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $20.98 | 2023 | Dificid |
| Vivus LLC | $20.52 | 2025 | Pancreaze |
| Pfizer INC. | $19.73 | 2025 | |
| Novo Nordisk INC | $14.67 | 2025 | Wegovy |
| Amgen INC. | $11.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hadi Atassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.